# 68Ga-AlfatideII for the Differential Diagnosis of of Lung Cancer and Lung Tuberculosis by PET/CT

> **NCT02481726** · PHASE1,PHASE2 · COMPLETED · sponsor: **Xijing Hospital** · enrollment: 31 (actual)

## Conditions studied

- Lung Cancer
- Lung Tuberculosis

## Interventions

- **RADIATION:** 68Ga-labeled peptides of dimer RGD (Alfatide II) and 18F-FDG

## Key facts

- **NCT ID:** NCT02481726
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-10
- **Final completion:** —
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2015-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02481726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02481726, "68Ga-AlfatideII for the Differential Diagnosis of of Lung Cancer and Lung Tuberculosis by PET/CT". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02481726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*